RxDoctor Payments Data

Ritchard Rosen, DPM

Podiatrist · Englewood, NJNPI 1972546430

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $35,078 of the $43,622 with a category attached, or 80.4%. 39 manufacturers reported payments, led by Osteomed LLC at 49.3% of the total. Among podiatrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$43,622in general payments, 2019–2025

Across 299 payments — averaging $145.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Osteomed LLC$22K
  • Acumed LLC$14K
  • Stryker$3K
  • Smith+Nephew$2K
  • Integra Lifesciences Corporation$972
  • Kerecis Limited$565
  • plus $2K from 33 others
$675in research payments, 2019–2025

Across 1 payment — averaging $675.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Reddress LTD$675

What the payments were for

  • Royalty or licence$35,07880%
  • Food & beverage$8,10719%
  • Other$4371%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,622 in reported general payments places this provider in the 95th percentile of 382 podiatrist providers in New Jersey.

See all podiatrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$179,211
Medicare patients
494
Services billed
2,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.29$59,162
Pregabalin109$4,259
Ciclopirox14$628
Ammonium Lactate18$319
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$300
Gabapentin20$214
Doxycycline Hyclate25$209
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$133
Meloxicam55$117
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,633$59,16229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 podiatrist providers in New Jersey.

Other podiatrist in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →